Pain Therapeutics Publishes Novel Approach to Treat Alzheimer's Disease; NOVAVAX and PATH Announce Partnership on RSV Vaccine Print E-mail
By Staff and Wire Reports   
Wednesday, 18 July 2012 19:11
Below is a look at some of the headlines for companies that made news in the healthcare sector on July 18, 2012.

Pain Therapeutics (Nasdaq: PTIE)
announced the publication of preclinical data that demonstrate a promising new approach to treat Alzheimer's disease.

Patients with Alzheimer's disease (AD) suffer from progressive and irreversible cognitive impairment that is widely believed to be caused by a protein called beta-amyloid. Scientists at City University of New York Medical School and Pain Therapeutics have now shown that a novel compound, PTI-125, can dramatically suppress the toxic effects of beta-amyloid.

Results were demonstrated in a mouse model of AD, and remarkably, in brain tissue from deceased Alzheimer's patients. These novel findings suggest PTI-125 may improve cognition and protect against the toxic effect of beta-amyloid in neurons, raising hopes for a treatment to combat cognitive decline in AD. Today's publication also suggests the usefulness of this new approach to develop a noninvasive, blood-based biomarker and clinical diagnostic for AD.


Novavax, Inc. (Nasdaq: NVAX) announced a clinical development partnership with PATH to develop its RSV (respiratory syncytial virus) vaccine to protect infants through maternal immunization in low-resource countries.

Novavax has been awarded approximately $2 million by PATH for initial funding under the partnership to partially support a Phase II dose-ranging clinical trial in women of childbearing age planned for the second half of this year. Following this initial study, PATH may elect to continue to partner with Novavax and provide support for the external clinical development costs through commercialization for this indication.

Also Wednesday:

, ( Collagenna Skin Care Products/Melem Secret has made an offer to merge with an existing Vitamin E-Commerce Super Store.

This document corrects and replaces the press release sent on July 18, 2012 at 11:55 AM ET.  Axia Group (PINKSHEETS:AGIJ) ( Collagenna Skin Care Products/Melem Secret has made a firm offer to merge with an existing Vitamin E-Commerce Super Store.

Boston Scientific Corporation (NYSE: BSX)
has presented results of two studies evaluating the Infinion™ 16 Percutaneous Lead, the world's first and only 16-contact percutaneous lead for spinal cord stimulation (SCS) therapy, and the Clik™ Anchor, an innovative locking system designed to secure and reduce unwanted migration of SCS leads.

Cytomedix, Inc. (OTCBB: CMXI)
(the "Company"), a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies, announces the initiation of a Phase I clinical study with ALD-451 in brain cancer patients in collaboration with Duke University Medical Center.

Daxor Corporation (NYSE MKT: DXR)
, an investment company with medical instrumentation and biotechnology operations, today announced the placement of Daxor's BVA-100 Blood Volume Analyzer at New York Presbyterian/Weill Cornell Medical Center.

Deaf-Talk, Inc. (PINKSHEETS: MGQG)
, dba DT Interpreting (DTI), the industry leader in on-demand video sign language interpreting, today announced the release of its unaudited financial statements for the fiscal year ending April 30, 2012.

Discovery Laboratories, Inc. (Nasdaq: DSCO)
today announced it has received a patent issued by the United States Patent and Trademark Office (USPTO) entitled "Pulmonary Surfactant Formulations and Methods for Promoting Mucus Clearance."

has entered into a worldwide exclusive Supply and Support Agreement with a major international glass company.

Life Technologies Corporation (NASDAQ:  LIFE)
today announced it will use a fuel cell system to self-generate electricity for its company headquarters, along with its manufacturing and distribution center in Carlsbad, California.

Omeros Corporation (NASDAQ: OMER)
today reported that OMS824, the lead compound in the Company's phosphodiesterase 10 (PDE10) program for schizophrenia, has successfully completed all of the preclinical studies that Omeros expects will be necessary for the drug's planned Investigational New Drug Application (IND).

PDI, Inc. (Nasdaq: PDII)
today announced that the client related to a previously disclosed contract has received FDA approval to market its product. PDI had entered into an agreement with that client to provide an array of promotional services for this product, including but not limited to a dedicated sales team, as well as teledetailing and digital communications through PDI's Group DCA division.

today announced a new research collaboration with Brigham and Women's Hospital (BWH), a teaching and research affiliate of Harvard Medical School, focused on immunology of type 1 diabetes.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus